dabigatran has been researched along with Disease Exacerbation in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, H; Hanley, DF; Marsh, EB; Nyquist, PA; Shin, SS; Ziai, WC | 1 |
| Brown, J; Diaby, V; Kim, S; Lingineni, K; Pham, PN; Schmidt, S; Wang, CY | 1 |
| Gong, JH; Liu, GJ; Sun, ZQ; Zhou, F | 1 |
| Cheon, K; Cho, HJ; Choi, HY; Han, SW; Heo, JH; Jung, YH; Kim, YD; Lee, HS; Lee, KY; Nam, HS; Park, HJ; Park, JH | 1 |
| Cipriano, LE; Hachinski, V; Lee, SAW; Ruiz Vargas, E; Sposato, LA | 1 |
| Buijs, JT; Crooijmans, JJ; Kroone, C; Laghmani, EH; Le Dévédec, SE; Tieken, C; van den Akker, RFP; van der Molen, KM; van der Pluijm, G; Versteeg, HH; Vletter, EM | 1 |
| Biessen, EA; Borissoff, JI; Daemen, MJ; Degen, JL; Esmon, CT; Hackeng, TM; Hamulyák, K; Heeneman, S; Leenders, P; Loubele, ST; Otten, JJ; Soehnlein, O; Spronk, HM; ten Cate, H; van Oerle, R; van Ryn, J; Weiler, H | 1 |
| Kamphuisen, PW; Lisman, T; Northup, PG; Porte, RJ | 1 |
| Alexander, ET; Gilmour, SK; Goss, A; Hayes, CS; Minton, AR; Van Ryn, J | 1 |
| Bea, F; Cabbage, S; Ieronimakis, N; Preusch, MR; Reyes, M; Ricks, J; Rosenfeld, ME; van Ryn, J; Wijelath, ES | 1 |
| Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J | 1 |
| Chernick, M; DeFeo, K; Gilmour, SK; Hayes, C; Ryn, JV | 1 |
1 review(s) available for dabigatran and Disease Exacerbation
| Article | Year |
|---|---|
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Progression; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Liver Cirrhosis; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2013 |
11 other study(ies) available for dabigatran and Disease Exacerbation
| Article | Year |
|---|---|
Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin k Antagonists.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Blood Coagulation Factors; Coagulants; Dabigatran; Disease Progression; Factor Xa Inhibitors; Female; Glasgow Outcome Scale; Humans; Intracranial Hemorrhage, Traumatic; Length of Stay; Male; Middle Aged; Mortality; Neurosurgical Procedures; Plasma; Platelet Transfusion; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Vitamin K; Warfarin | 2020 |
Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Computer Simulation; Cost-Benefit Analysis; Dabigatran; Disease Progression; Drug Costs; Drug Substitution; Drugs, Generic; Female; Humans; Male; Markov Chains; Models, Biological; Models, Economic; Quality-Adjusted Life Years; Stroke; Therapeutic Equivalency; Treatment Outcome; United States; Young Adult | 2020 |
Dabigatran-induced chronic progressive immune hemolytic anemia: A case report.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antithrombins; Chronic Disease; Dabigatran; Disease Progression; Drug Substitution; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Male; Treatment Outcome; Warfarin | 2020 |
Stroke Severity in Patients on Non-Vitamin K Antagonist Oral Anticoagulants with a Standard or Insufficient Dose.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Disease Progression; Drug Dosage Calculations; Drug Therapy, Combination; Female; Humans; Korea; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Stroke; Treatment Outcome; Warfarin | 2018 |
Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Disease Progression; Health Care Costs; Humans; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Topics: Animals; Anticoagulants; Antithrombins; Breast Neoplasms; Cell Line, Tumor; Dabigatran; Disease Progression; Factor Xa Inhibitors; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Rivaroxaban; Triple Negative Breast Neoplasms; Venous Thromboembolism; Xenograft Model Antitumor Assays | 2019 |
Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Benzimidazoles; Blood Coagulation; Dabigatran; Disease Models, Animal; Disease Progression; Female; Hematopoiesis; Inflammation; Mice; Mice, Knockout; Neutrophils; Phenotype; Plaque, Atherosclerotic; Pyridines; Reactive Oxygen Species; Thrombin; Thrombosis | 2013 |
Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasis.
Topics: Animals; Antineoplastic Agents, Alkylating; Antithrombins; Cell Line, Tumor; Cell-Derived Microparticles; Cyclophosphamide; Dabigatran; Disease Models, Animal; Disease Progression; Drug Synergism; Female; Mice; Myeloid Cells; Neoplasm Metastasis; Neoplasms; Platelet Activation; Thrombin; Thromboplastin | 2015 |
Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice.
Topics: Age Factors; Animals; Antithrombins; Apolipoproteins E; Atherosclerosis; Dabigatran; Disease Models, Animal; Disease Progression; Flow Cytometry; Leukocyte Common Antigens; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oncostatin M; Sinus of Valsalva | 2015 |
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism.
Topics: Animals; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Disease Models, Animal; Disease Progression; Embolization, Therapeutic; Female; Femoral Vein; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Lung; Mice; Mice, Inbred C57BL; Microscopy, Video; Pulmonary Embolism; Thrombosis; Venous Thromboembolism; Venous Thrombosis | 2016 |
Use of dabigatran etexilate to reduce breast cancer progression.
Topics: Animals; Antithrombin Proteins; Benzimidazoles; Breast Neoplasms; Cell Adhesion; Cell Movement; Cells, Cultured; Dabigatran; Disease Progression; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; NIH 3T3 Cells; Pyridines; Rats; Thrombin; Trachea | 2010 |